NCT07295769 Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause
| NCT ID | NCT07295769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Asan Medical Center |
| Condition | Embolic Stroke of Undetermined Source |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-01-28 |
| Primary Completion | 2028-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-01-28 with a primary completion date of 2028-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO Patch M, MEMO Patch2) in 100 patients with Embolic Stroke of Undetermined Source (ESUS) who require atrial fibrillation screening. Participants who meet all inclusion and exclusion criteria and provide written informed consent will wear the MEMO Patch M and undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. During hospitalization, 24-hour Holter monitoring will also be conducted. Before discharge, the investigator will review these results to determine whether implantable loop recorder (ILR) implantation is necessary. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG monitoring period. One month after discharge, the investigator will review the results of the first monitoring and initiate the second ECG monitoring with MEMO Patch2. Three months after discharge, the results of the second ECG monitoring will be reviewed, and participation in the clinical trial will be completed.
Eligibility Criteria
Inclusion Criteria: Participants may take part in this clinical study only if they meet all of the following criteria: 1. Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study 2. Patients diagnosed with ESUS (Embolic Stroke of Undetermined Source) 3. Patients who require in-hospital or out-of-hospital electrocardiographic (ECG) monitoring Exclusion Criteria: Participants who meet any of the following criteria cannot be enrolled in this clinical study: 1. Individuals already diagnosed with atrial fibrillation or atrial flutter 2. Individuals with a clearly identified cause of stroke 3. Individuals known to have allergic reactions to adhesives or hydrogels 4. Individuals who, in the investigator's judgment, have cognitive vulnerability that makes it difficult to understand the study information and voluntarily decide on participation 5. Any other individuals whom the principal investigator considers to be at potential risk by participating in the study or otherwise unsuitable for participation
Contact & Investigator
Bum Joon Kim
PRINCIPAL INVESTIGATOR
Asan Medical Center
Frequently Asked Questions
Who can join the NCT07295769 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Embolic Stroke of Undetermined Source. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07295769 currently recruiting?
Yes, NCT07295769 is actively recruiting participants. Contact the research team at medicj80@hanmail.net for enrollment information.
Where is the NCT07295769 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07295769 clinical trial?
NCT07295769 is sponsored by Asan Medical Center. The principal investigator is Bum Joon Kim at Asan Medical Center. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.